Cell Source, Inc. Contracts & Agreements

Common Stock Purchase Agreement, dated as of August 20, 2024, between Cell Source, Inc. and the investors identified therein (Filed With SEC on November 14, 2024)

Amendment No. 3 to Veto Cell Production and Clinical Trial Program Agreement, dated as of May 1, 2023, between Cell Source Limited and the University of Texas M.D. Cancer Center (Filed With SEC on August 19, 2024)

Amendment No. 2 to Veto Cell Production and Clinical Trial Program Agreement, dated as of August 7, 2019, between Cell Source Limited and the University of Texas M.D. Cancer Center (Filed With SEC on August 19, 2024)

Original Issue Discount Note issued to Darlene Soave Revocable Trust (Filed With SEC on June 24, 2024)

Original Issue Discount Note issued to David Zolty Investment ULC (Filed With SEC on June 24, 2024)

Original Issue Discount Note issued to Solomon Zolty Investment ULC (Filed With SEC on June 24, 2024)

Original Issue Discount Note issued to Phyllis Friedman Investment ULC (Filed With SEC on June 24, 2024)

Original Issue Discount Note issued to Honey Kamenetsky Investment ULC (Filed With SEC on June 24, 2024)

Original Issue Discount Note issued to Helen Samuels Investment ULC (Filed With SEC on June 24, 2024)

Amendment No. 3 to Sponsored Research Agreement dated November 15, 2022 between the University of Texas MD Anderson Cancer Center and Cell Source Ltd (Filed With SEC on November 9, 2023)

Amendment No. 4 to Sponsored Research Agreement dated November 6, 2023 between the University of Texas MD Anderson Cancer Center and Cell Source Ltd (Filed With SEC on November 9, 2023)

Amendment No. 4 to Third Amended and Restated Note (Filed With SEC on November 9, 2023)

Amendment No. 2 to 10% Convertible Note (Filed With SEC on November 9, 2023)

Amendment No. 3 to Third Amended and Restated Note (Filed With SEC on August 8, 2023)

Amendment No. 1 to10% Convertible Note (Filed With SEC on August 8, 2023)

Amendment No. 2 to Third Amended and Restated Note (Filed With SEC on August 8, 2023)

Amendment No. 1 to Third Amended and Restated Note (Filed With SEC on August 8, 2023)

Description of Common Stock (Filed With SEC on April 15, 2022)

Fifth Amendment to Research and License Agreement dated as of June 30, 2019 between the Company and Yeda Research and Development Company Limited (Filed With SEC on April 15, 2022)

Amendment No. 2 to Sponsored Research Agreement dated October 18, 2021 between the University of Texas MD Anderson Cancer Center and Cell Source Ltd (Filed With SEC on April 15, 2022)

Eighth Amendment to Research and License Agreement dated as of December 2, 2021 between the Company and Yeda Research and Development Company Limited (Filed With SEC on April 15, 2022)

10% Convertible Note issued to George Verstraete (Filed With SEC on April 15, 2022)

Amendment No. 2 to Sponsored Research Agreement dated October 18, 2021 between The University of Texas M.D. Anderson Cancer Center and Cell Source Limited (Filed With SEC on November 15, 2021)

Third Amended and Restated 10.0% Convertible Note (Filed With SEC on August 12, 2021)

Form of Note Exchange Agreement between Cell Source, Inc. and holder of 10% OID Convertible Promissory Note (Filed With SEC on April 15, 2021)

Second Amended and Restated 10.0% Convertible Note (Filed With SEC on April 15, 2021)

Form of warrant issued to holder of Second Amended and Restated 10.0% Convertible Note (Filed With SEC on April 15, 2021)

Seventh Amendment to Research and License Agreement dated November 15, 2020 between Yeda Research and Development Company Limited and Cell Source Limited (Filed With SEC on April 15, 2021)

Form of Warrant issued to Purchasers of 8% Convertible Promissory Note (Filed With SEC on November 13, 2020)

Form of Warrant issued to Members of Scientific Advisory Board (Filed With SEC on November 13, 2020)

Form of Warrant issued to Service Providers (Filed With SEC on November 13, 2020)

Form of Director Stock Option Agreement (Filed With SEC on November 13, 2020)

Form of Consultant Stock Option Agreement (Filed With SEC on November 13, 2020)

Form of 8% Convertible Promissory Note (Filed With SEC on November 13, 2020)

Form of Warrant issued to purchaser of 10% OID Convertible Promissory Note (Filed With SEC on August 14, 2020)

Form of 10% OID Convertible Promissory Note (Filed With SEC on August 14, 2020)

Form of Securities Purchase Agreement between Cell Source, Inc. and the purchaser of 10% OID Convertible Promissory Note (Filed With SEC on August 14, 2020)

Form of Placement Agent Warrant dated February 13, 2020 (Filed With SEC on May 15, 2020)

Convertible Promissory Note dated January 10, 2020 (Filed With SEC on May 15, 2020)

Sixth Amendment to Research and License Agreement effective December 31, 2019 between Yeda Research and Development Company Limited and Cell Source Limited (Filed With SEC on March 30, 2020)

Convertible Note effective October 28, 2019 (Filed With SEC on March 30, 2020)

CELL SOURCE, INC. 2019 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT (Filed With SEC on August 14, 2019)

CELL SOURCE, INC. 2019 EQUITY INCENTIVE PLAN (Filed With SEC on August 14, 2019)

AMENDMENT NO. 1 TO VETO CELL PRODUCTION AND CLINICAL TRIAL PROGRAM AGREEMENT (Filed With SEC on May 20, 2019)

SPONSORED RESEARCH AGREEMENT (Filed With SEC on April 1, 2019)

§ 1 Subject matter (Filed With SEC on April 1, 2019)

WARRANT (Filed With SEC on July 25, 2018)

FOURTH AMENDMENT TO RESEARCH AND LICENCE AGREEMENT (this Amendment) Effective Date: March 30, 2018 By and between YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED a company duly... (Filed With SEC on July 25, 2018)

THIRD AMENDMENT TO RESEARCH AND LICENCE AGREEMENT Made and entered in to this 29th day of March, 2018 By and between YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED a company duly... (Filed With SEC on July 25, 2018)

SECOND AMENDMENT TO RESEARCH AND LICENCE AGREEMENT (this Amendment) Effective Date: November 28, 2016 By and between YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED a company duly... (Filed With SEC on July 25, 2018)

PROMISSORY NOTE (Filed With SEC on August 15, 2016)

Original Issue Date: January 27, 2015$250,000.00 CONVERTIBLE NOTE DUE JULY 27, 2016 (Filed With SEC on May 13, 2016)

PROMISSORY NOTE OF CELL SOURCE, INC. (Filed With SEC on April 14, 2016)

WARRANT (Filed With SEC on April 14, 2016)

CONVERTIBLE NOTE DUE [*], 20[*] (Filed With SEC on April 14, 2016)

SUBSCRIPTION AGREEMENT (Filed With SEC on April 14, 2016)

By:Name:Title:Cell Source, Inc. (Filed With SEC on November 16, 2015)

WARRANT (Filed With SEC on July 28, 2015)

CONVERTIBLE PROMISSORY NOTE OF CELL SOURCE, INC. (Filed With SEC on July 28, 2015)

WARRANT (Filed With SEC on July 28, 2015)

PROMISSORY NOTE OF CELL SOURCE, INC. (Filed With SEC on July 28, 2015)

CONSULTING/ADVISORY AGREEMENT (Filed With SEC on June 10, 2015)

PROMISSORY NOTE OF CELL SOURCE, INC. (Filed With SEC on June 3, 2015)

WARRANT TO PURCHASE COMMON STOCK VOID AFTER 5:30 P.M., EASTERN TIME, ON THE EXPIRATION DATE (Filed With SEC on June 3, 2015)

CELL SOURCE, INC. 65 Yigal Alon Street Tel Aviv, Israel 67433 (Filed With SEC on June 3, 2015)

WARRANT TO PURCHASE COMMON STOCK VOID AFTER 5:30 P.M., EASTERN TIME, ON THE EXPIRATION DATE (Filed With SEC on April 1, 2015)

PROMISSORY NOTE OF CELL SOURCE, INC. (Filed With SEC on April 1, 2015)

PROMISSORY NOTE (Filed With SEC on December 2, 2014)

BRIDGEFUNDING AGREEMENT Made and signed as of the 23rd day of October,2013 (Filed With SEC on September 23, 2014)

THIRD AMENDMENT TO EVALUATION AND EXCLUSIVEOPTION AGREEMENT Made and entered in to this 15th day ofAugust, 2014 By and between YEDA RESEARCH AND DEVELOPMENT COMPANYLIMITED a... (Filed With SEC on August 19, 2014)

AMENDMENT NO.1 TO REGISTRATION RIGHTSAGREEMENT (Filed With SEC on August 8, 2014)

SHARE EXCHANGE AGREEMENT (Filed With SEC on July 1, 2014)

SUBSCRIPTION AGREEMENT (Filed With SEC on July 1, 2014)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on July 1, 2014)

CELL SOURCE, LTD. WARRANT TO PURCHASE ORDINARY SHARES (Filed With SEC on July 1, 2014)

Cell Source, Inc. . Warrant to Purchase Common Stock (Filed With SEC on July 1, 2014)

WARRANT TO PURCHASE COMMON STOCK VOID AFTER 5:30 P.M., EASTERN TIME, ON THE EXPIRATION DATE (Filed With SEC on July 1, 2014)

Category

Industry

Companies

Contracts

Cell Source, Inc. Contracts & Agreements